MedDataX Logo

Novel Regimens in COVID-19 Treatment

NCT ID: NCT04382846

Last Updated: 2020-12-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-08

Study Completion Date

2030-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019. Some studies demonstrated the efficacy of combined regimen of nitazoxanide and azithromycin or ivermectin and chloroquine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID Corona Virus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nitazoxanide

Nitazoxanide with standard protocol of treatment

Group Type EXPERIMENTAL

Nitazoxanide

Intervention Type DRUG

Nitazoxanide

Control group

Standard protocol alone

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nitazoxanide

Nitazoxanide

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Parazoxanide, Nanazoxid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with COVID-19 infection

Exclusion Criteria

* Allergy or contraindication to the drugs.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sherief Abd-Elsalam

Ass. Prof. Tropical Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

sherief Abd-Elsalam, Ass. Prof.

Role: PRINCIPAL_INVESTIGATOR

ass. Prof. Tropical Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tanta University, Assiut University

Tanta, , Egypt

Site Status RECRUITING

Sherief Abd-Elsalam

Tanta, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sherief Abd-Elsalam, ass. prof.

Role: CONTACT

Phone: 00201147773440

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sherief Abd-Elsalam

Role: primary

sherief abd-elsalam

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Kelleni MT. Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management. Pharmacol Res. 2020 Jul;157:104874. doi: 10.1016/j.phrs.2020.104874. Epub 2020 Apr 30.

Reference Type BACKGROUND
PMID: 32360581 (View on PubMed)

Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020 Apr 22;35:100684. doi: 10.1016/j.nmni.2020.100684. eCollection 2020 May.

Reference Type BACKGROUND
PMID: 32322397 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

tanta covid treatment

Identifier Type: -

Identifier Source: org_study_id